288 related articles for article (PubMed ID: 31868150)
1. Alternative and New Radiopharmaceutical Agents for Lung Cancer.
Telo S; Calderoni L; Vichi S; Zagni F; Castellucci P; Fanti S
Curr Radiopharm; 2020; 13(3):185-194. PubMed ID: 31868150
[TBL] [Abstract][Full Text] [Related]
2. The role of new PET tracers for lung cancer.
Szyszko TA; Yip C; Szlosarek P; Goh V; Cook GJ
Lung Cancer; 2016 Apr; 94():7-14. PubMed ID: 26973200
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
5. The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis.
Jiang Y; Hou G; Cheng W
Medicine (Baltimore); 2019 Mar; 98(10):e14769. PubMed ID: 30855482
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
8. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
9. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
[TBL] [Abstract][Full Text] [Related]
10. Non-Small-Cell Lung Cancer PET Imaging Beyond F18 Fluorodeoxyglucose.
Cheng G
PET Clin; 2018 Jan; 13(1):73-81. PubMed ID: 29157387
[TBL] [Abstract][Full Text] [Related]
11. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
12. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
13. Advances in positron emission tomographic imaging of lung cancer.
Chen DL; Dehdashti F
Proc Am Thorac Soc; 2005; 2(6):541-4, 512. PubMed ID: 16352762
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of findings and usefulness of integrated PET/CT in patients with known or suspected neuroendocrine tumors of the lung.
Chong S; Lee KS
Cancer Imaging; 2007 Nov; 7(1):195-201. PubMed ID: 18055292
[TBL] [Abstract][Full Text] [Related]
15. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
Evangelista L; Ravelli I; Bignotto A; Cecchin D; Zucchetta P
Clin Imaging; 2020 Nov; 67():113-116. PubMed ID: 32559681
[TBL] [Abstract][Full Text] [Related]
16. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
[TBL] [Abstract][Full Text] [Related]
17. Vaccine-Related Lymph Nodes: The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET/CT in the Era of COVID-19 Vaccination.
Ah-Thiane L; Ferrer L; Maucherat B; Fleury V; Le Thiec M; Rusu D; Rousseau C
Clin Nucl Med; 2022 Jul; 47(7):575-582. PubMed ID: 35675134
[TBL] [Abstract][Full Text] [Related]
18. Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review.
Ryzhkova D; Mitrofanova L; Tsoy U; Grineva E; Schlyakhto E
Front Endocrinol (Lausanne); 2022; 13():958442. PubMed ID: 36133304
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
